[
  {
    "ts": null,
    "headline": "Stocks to Watch Recap: Home Depot, Tesla, Uber, UnitedHealth",
    "summary": "After-Hours Earnings: Shares of Palo Alto Networks (PANW) fell about 4% after the cybersecurity company reported quarterly results, while shares of home builder Toll Brothers (TOL) climbed 6% after its results.",
    "url": "https://finnhub.io/api/news?id=4913c7407983450fdb34f679739b08f34f37aeaf29deaa61b6854e5856e434d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747774910,
      "headline": "Stocks to Watch Recap: Home Depot, Tesla, Uber, UnitedHealth",
      "id": 134628378,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "After-Hours Earnings: Shares of Palo Alto Networks (PANW) fell about 4% after the cybersecurity company reported quarterly results, while shares of home builder Toll Brothers (TOL) climbed 6% after its results.",
      "url": "https://finnhub.io/api/news?id=4913c7407983450fdb34f679739b08f34f37aeaf29deaa61b6854e5856e434d4"
    }
  },
  {
    "ts": null,
    "headline": "Trump's Drug Price War Could Slash Big Pharma Profits",
    "summary": "New HHS push ties U.S. drug prices to global lows, threatening margins for top biopharma giants",
    "url": "https://finnhub.io/api/news?id=98fecc8ed73a17b35ae2fe4c738b7e01393d2226c64ea1fc835ebfb57df28733",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747772028,
      "headline": "Trump's Drug Price War Could Slash Big Pharma Profits",
      "id": 134628542,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "New HHS push ties U.S. drug prices to global lows, threatening margins for top biopharma giants",
      "url": "https://finnhub.io/api/news?id=98fecc8ed73a17b35ae2fe4c738b7e01393d2226c64ea1fc835ebfb57df28733"
    }
  },
  {
    "ts": null,
    "headline": "BMO Capital Maintains Buy Rating on Pfizer (PFE) Stock",
    "summary": "On May 20, BMO Capital analyst Evan Seigerman maintained a Buy rating on Pfizer Inc. (NYSE:PFE) and kept the price target the same at $30. The reiteration comes after the company recently announced entering into an exclusive licensing agreement with 3SBio, a leading Chinese biopharmaceutical company. The agreement entails the development, manufacturing, and commercialization of […]",
    "url": "https://finnhub.io/api/news?id=60adb929bfbf44ca8ae67cdf0179113791bd5a7697d5e64b8ab74d9d8eedfef1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747771836,
      "headline": "BMO Capital Maintains Buy Rating on Pfizer (PFE) Stock",
      "id": 134628543,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "On May 20, BMO Capital analyst Evan Seigerman maintained a Buy rating on Pfizer Inc. (NYSE:PFE) and kept the price target the same at $30. The reiteration comes after the company recently announced entering into an exclusive licensing agreement with 3SBio, a leading Chinese biopharmaceutical company. The agreement entails the development, manufacturing, and commercialization of […]",
      "url": "https://finnhub.io/api/news?id=60adb929bfbf44ca8ae67cdf0179113791bd5a7697d5e64b8ab74d9d8eedfef1"
    }
  },
  {
    "ts": null,
    "headline": "COVID vaccine guidelines, D-Wave, Viking Cruises: Trending Tickers",
    "summary": "The US Food and Drug Administration (FDA) announces new regulatory guidelines for future COVID-19 vaccines and booster shots. Moderna (MRNA) and Pfizer (PFE) shares move higher on this news, while Novavax (NVAX) takes a dip. D-Wave Quantum (QBTS) sees over 26% of stock gains ahead of Tuesday's market close after unveiling its Advantage 2 quantum computer. Cruiseline operator Viking Holdings (VIK) stock takes a hit today despite the company sharing strong first quarter earnings. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finnhub.io/api/news?id=1ca22bbec52c37aea49cc8ee611a94ecfdbf4308bad91cfa519f16a68f318726",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747770930,
      "headline": "COVID vaccine guidelines, D-Wave, Viking Cruises: Trending Tickers",
      "id": 134628544,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The US Food and Drug Administration (FDA) announces new regulatory guidelines for future COVID-19 vaccines and booster shots. Moderna (MRNA) and Pfizer (PFE) shares move higher on this news, while Novavax (NVAX) takes a dip. D-Wave Quantum (QBTS) sees over 26% of stock gains ahead of Tuesday's market close after unveiling its Advantage 2 quantum computer. Cruiseline operator Viking Holdings (VIK) stock takes a hit today despite the company sharing strong first quarter earnings. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
      "url": "https://finnhub.io/api/news?id=1ca22bbec52c37aea49cc8ee611a94ecfdbf4308bad91cfa519f16a68f318726"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Rise in Afternoon Trading",
    "summary": "Health care stocks advanced Tuesday afternoon, with the NYSE Health Care Index and the Health Care S",
    "url": "https://finnhub.io/api/news?id=9ffbe987c4da816129e8f1ad39d3a86106eb6db4d9dad4162ecdeb8e76d5fbf0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747764174,
      "headline": "Sector Update: Health Care Stocks Rise in Afternoon Trading",
      "id": 134628545,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Health care stocks advanced Tuesday afternoon, with the NYSE Health Care Index and the Health Care S",
      "url": "https://finnhub.io/api/news?id=9ffbe987c4da816129e8f1ad39d3a86106eb6db4d9dad4162ecdeb8e76d5fbf0"
    }
  },
  {
    "ts": null,
    "headline": "Bitcoin gains, FDA's vaccine guidance, UnitedHealth recovers",
    "summary": "Yahoo Finance host Josh Lipton tracks today's top moving stocks and biggest market stories in this Market Minute, including bitcoin's (BTC-USD) gains stemming from Senate lawmakers voting on the GENIUS Act, Food and Drug Administration (FDA) officials providing new guidance around COVID-19 vaccine booster shots, and UnitedHealth Group shares (UNH) on pace to recover from last week's losses. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=e96de132cc92cbd3f800b8713abdfbd780a12d5b424a8ce8ecb0e3b05e1f7c56",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747761155,
      "headline": "Bitcoin gains, FDA's vaccine guidance, UnitedHealth recovers",
      "id": 134628546,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Yahoo Finance host Josh Lipton tracks today's top moving stocks and biggest market stories in this Market Minute, including bitcoin's (BTC-USD) gains stemming from Senate lawmakers voting on the GENIUS Act, Food and Drug Administration (FDA) officials providing new guidance around COVID-19 vaccine booster shots, and UnitedHealth Group shares (UNH) on pace to recover from last week's losses. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=e96de132cc92cbd3f800b8713abdfbd780a12d5b424a8ce8ecb0e3b05e1f7c56"
    }
  },
  {
    "ts": null,
    "headline": "The FDA Is Limiting Covid Shots. But Moderna, Vaccine Stocks Jumped.",
    "summary": "The FDA said Tuesday it will limit future Covid vaccines to older and at-risk Americans. The move buoyed Moderna, BioNTech and Novavax.",
    "url": "https://finnhub.io/api/news?id=2cddd5105cf0b0b61e36cd86e96423c2bbc1d97b3964cb313aec5fef21068b14",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747758125,
      "headline": "The FDA Is Limiting Covid Shots. But Moderna, Vaccine Stocks Jumped.",
      "id": 134628547,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The FDA said Tuesday it will limit future Covid vaccines to older and at-risk Americans. The move buoyed Moderna, BioNTech and Novavax.",
      "url": "https://finnhub.io/api/news?id=2cddd5105cf0b0b61e36cd86e96423c2bbc1d97b3964cb313aec5fef21068b14"
    }
  },
  {
    "ts": null,
    "headline": "FDA tightens requirements for COVID vaccine, adding trials for healthy adults",
    "summary": "The U.S. Food and DrugAdministration on Tuesday said it plans to require new clinicaltrials for approval of annual COVID-19 boosters for healthyAmericans under age 65, effectively limiting them to...",
    "url": "https://finnhub.io/api/news?id=cb6b9494e4bfc13d1e0cc5aa4faa92fd8ad51720c5de674b91d5fdfbe87e2722",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747755009,
      "headline": "FDA tightens requirements for COVID vaccine, adding trials for healthy adults",
      "id": 134618602,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "The U.S. Food and DrugAdministration on Tuesday said it plans to require new clinicaltrials for approval of annual COVID-19 boosters for healthyAmericans under age 65, effectively limiting them to...",
      "url": "https://finnhub.io/api/news?id=cb6b9494e4bfc13d1e0cc5aa4faa92fd8ad51720c5de674b91d5fdfbe87e2722"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Is Jumping Into a Hot Cancer-Drug Race. It May Have Overpaid.",
    "summary": "The company bought the rights to an experimental cancer drug for $1.3 billion, plus potential milestone payments of $4.8 billion, as well as royalties if the treatment is approved.",
    "url": "https://finnhub.io/api/news?id=9b9aee95fe79b9b494f7b4ff179d2062dd0133a32375637b318c6f6c183ba6af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747752360,
      "headline": "Pfizer Is Jumping Into a Hot Cancer-Drug Race. It May Have Overpaid.",
      "id": 134628548,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The company bought the rights to an experimental cancer drug for $1.3 billion, plus potential milestone payments of $4.8 billion, as well as royalties if the treatment is approved.",
      "url": "https://finnhub.io/api/news?id=9b9aee95fe79b9b494f7b4ff179d2062dd0133a32375637b318c6f6c183ba6af"
    }
  },
  {
    "ts": null,
    "headline": "MRK, Daiichi Begin Pivotal Esophageal Cancer Study With ADC Drug",
    "summary": "The IDeate-Esophageal01 study is set to evaluate Merck & Daiichi's ADC drug ifinatamab deruxtecan in pre-treated patients with esophageal squamous cell carcinoma.",
    "url": "https://finnhub.io/api/news?id=dac962584a640d337c6a50b506ba01828835d36c14770e9b026af1e8da6c827b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747750920,
      "headline": "MRK, Daiichi Begin Pivotal Esophageal Cancer Study With ADC Drug",
      "id": 134628549,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The IDeate-Esophageal01 study is set to evaluate Merck & Daiichi's ADC drug ifinatamab deruxtecan in pre-treated patients with esophageal squamous cell carcinoma.",
      "url": "https://finnhub.io/api/news?id=dac962584a640d337c6a50b506ba01828835d36c14770e9b026af1e8da6c827b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China",
    "summary": "Pfizer has announced a new agreement to develop and market a cancer drug being developed by Chinese drugmaker 3SBio.",
    "url": "https://finnhub.io/api/news?id=0e1b0e7b77e00987eab0f4e05e0cb718e6380eb25645e6e5feb641ab8159e078",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747748087,
      "headline": "Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China",
      "id": 134628550,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer has announced a new agreement to develop and market a cancer drug being developed by Chinese drugmaker 3SBio.",
      "url": "https://finnhub.io/api/news?id=0e1b0e7b77e00987eab0f4e05e0cb718e6380eb25645e6e5feb641ab8159e078"
    }
  },
  {
    "ts": null,
    "headline": "Buy 3 Wide Moat Stocks With Double-Digit Near-Term Upside Potential",
    "summary": "Three Wide Mode stocks with strong short-term upsides are: PFE, KO, DIS.",
    "url": "https://finnhub.io/api/news?id=fec77c22380bd244a356b44f86bf5723038e3432268bfc65601a8814eb95290b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747746000,
      "headline": "Buy 3 Wide Moat Stocks With Double-Digit Near-Term Upside Potential",
      "id": 134628254,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Three Wide Mode stocks with strong short-term upsides are: PFE, KO, DIS.",
      "url": "https://finnhub.io/api/news?id=fec77c22380bd244a356b44f86bf5723038e3432268bfc65601a8814eb95290b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Buys Rights to PD-1 & VEGF Inhibitor From China Biotech",
    "summary": "PFE in-licenses global rights, ex-China, to SSGJ-707, from Chinese biotech, 3SBio for an upfront payment of $1.25 billion.",
    "url": "https://finnhub.io/api/news?id=4aef1be11875bec3c539adff654cafe2a0868c7656e8fa5401ea40c34d4f24fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747745160,
      "headline": "Pfizer Buys Rights to PD-1 & VEGF Inhibitor From China Biotech",
      "id": 134628552,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PFE in-licenses global rights, ex-China, to SSGJ-707, from Chinese biotech, 3SBio for an upfront payment of $1.25 billion.",
      "url": "https://finnhub.io/api/news?id=4aef1be11875bec3c539adff654cafe2a0868c7656e8fa5401ea40c34d4f24fd"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons Why Japan's Record Bond Yield Spike Matters",
    "summary": "Japan's bond yield surge hints at global market risks. See how it impacts U.S. Treasuries, the yen, and top investments like Toyota and Sony.",
    "url": "https://finnhub.io/api/news?id=7aa7a5385b694ca435ab7b1f935d5d6bd903354ebc7282f4d9c68563cb9c998b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747744205,
      "headline": "3 Reasons Why Japan's Record Bond Yield Spike Matters",
      "id": 134611311,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2161558032/image_2161558032.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Japan's bond yield surge hints at global market risks. See how it impacts U.S. Treasuries, the yen, and top investments like Toyota and Sony.",
      "url": "https://finnhub.io/api/news?id=7aa7a5385b694ca435ab7b1f935d5d6bd903354ebc7282f4d9c68563cb9c998b"
    }
  },
  {
    "ts": null,
    "headline": "FDA sets new COVID booster guidelines requiring trials for approvals for healthy adults",
    "summary": "The U.S. Food and DrugAdministration plans to require new clinical trials for approvalof annual COVID-19 boosters for healthy Americans under 65,effectively limiting their availability later this...",
    "url": "https://finnhub.io/api/news?id=bd6085fa34e4cdfe5af2c1c1bf49ae27f698ce39599dd1f3502e388c6d2a5107",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747742414,
      "headline": "FDA sets new COVID booster guidelines requiring trials for approvals for healthy adults",
      "id": 134610968,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "The U.S. Food and DrugAdministration plans to require new clinical trials for approvalof annual COVID-19 boosters for healthy Americans under 65,effectively limiting their availability later this...",
      "url": "https://finnhub.io/api/news?id=bd6085fa34e4cdfe5af2c1c1bf49ae27f698ce39599dd1f3502e388c6d2a5107"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Thinks Bigger With 3SBio Deal",
    "summary": "Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more on the deal and its PFE implications.",
    "url": "https://finnhub.io/api/news?id=7918c3401ea947a3f1e556c8c750590cadfe84268c9fc970598924192253611f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747741593,
      "headline": "Pfizer Thinks Bigger With 3SBio Deal",
      "id": 134611003,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/503019944/image_503019944.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more on the deal and its PFE implications.",
      "url": "https://finnhub.io/api/news?id=7918c3401ea947a3f1e556c8c750590cadfe84268c9fc970598924192253611f"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer makes a $6 billion run into a new cancer drug race, 6 months after rival",
    "summary": "Pfizer makes a $6 billion run into a new cancer drug race, 6 months after rival",
    "url": "https://finnhub.io/api/news?id=f66604d8d6de5ec076b6cd42f3bea6990511fc9586482bb59cbabb3c06b6753e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747739520,
      "headline": "Pfizer makes a $6 billion run into a new cancer drug race, 6 months after rival",
      "id": 134613538,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer makes a $6 billion run into a new cancer drug race, 6 months after rival",
      "url": "https://finnhub.io/api/news?id=f66604d8d6de5ec076b6cd42f3bea6990511fc9586482bb59cbabb3c06b6753e"
    }
  },
  {
    "ts": null,
    "headline": "US FDA advisers to consider if new COVID shots should target LP.8.1 subvariant",
    "summary": "Advisers to the U.S. Food and DrugAdministration will discuss whether to recommend COVID-19vaccines for 2025-26 for targeting the LP.8.1 subvariant,documents filed on Tuesday showed. ...",
    "url": "https://finnhub.io/api/news?id=370a97d057268d12c41a65ce66d713e95ca1deeabc54baa886177ace59bc87c2",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747739413,
      "headline": "US FDA advisers to consider if new COVID shots should target LP.8.1 subvariant",
      "id": 134610551,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Advisers to the U.S. Food and DrugAdministration will discuss whether to recommend COVID-19vaccines for 2025-26 for targeting the LP.8.1 subvariant,documents filed on Tuesday showed. ...",
      "url": "https://finnhub.io/api/news?id=370a97d057268d12c41a65ce66d713e95ca1deeabc54baa886177ace59bc87c2"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Strikes up to $6.05 Billion Licensing Deal for 3SBio's Cancer Drug Candidate",
    "summary": "Pfizer (PFE) secured exclusive global rights, excluding China, to biopharmaceutical firm 3SBio's can",
    "url": "https://finnhub.io/api/news?id=e80d287d16a51a78890524e293ceee8b47ef478b3f8f434b1c1ae06b0a7c1837",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747737131,
      "headline": "Pfizer Strikes up to $6.05 Billion Licensing Deal for 3SBio's Cancer Drug Candidate",
      "id": 134609204,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) secured exclusive global rights, excluding China, to biopharmaceutical firm 3SBio's can",
      "url": "https://finnhub.io/api/news?id=e80d287d16a51a78890524e293ceee8b47ef478b3f8f434b1c1ae06b0a7c1837"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Signs Experimental Drug Licensing Agreement With 3SBio",
    "summary": "Pfizer inks Experimental Drug Licensing Deal With China-based company 3SBio.",
    "url": "https://finnhub.io/api/news?id=77cb96cec2117014d4256c7af043fb80ac64cdde84dead921f948f65913cf224",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747736880,
      "headline": "Pfizer Signs Experimental Drug Licensing Agreement With 3SBio",
      "id": 134609064,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer inks Experimental Drug Licensing Deal With China-based company 3SBio.",
      "url": "https://finnhub.io/api/news?id=77cb96cec2117014d4256c7af043fb80ac64cdde84dead921f948f65913cf224"
    }
  },
  {
    "ts": null,
    "headline": "Trending tickers: Microsoft, Pfizer, Foxconn, CATL and Vodafone",
    "summary": "The latest investor updates on stocks that are trending on Tuesday.",
    "url": "https://finnhub.io/api/news?id=6bcef00cdbaa785102744a87e7fbd200a8d27a935e2a2099d18add641c3dcabb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747734621,
      "headline": "Trending tickers: Microsoft, Pfizer, Foxconn, CATL and Vodafone",
      "id": 134608892,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The latest investor updates on stocks that are trending on Tuesday.",
      "url": "https://finnhub.io/api/news?id=6bcef00cdbaa785102744a87e7fbd200a8d27a935e2a2099d18add641c3dcabb"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Better To Face The Harsh Reality Than Continue Waiting",
    "summary": "Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click to find out why PFE stock is a Hold.",
    "url": "https://finnhub.io/api/news?id=3bc12cc409f629dd3693f54ea9819d033d3bb70d51bf572bc2992b722db36ac2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747731600,
      "headline": "Pfizer: Better To Face The Harsh Reality Than Continue Waiting",
      "id": 134608644,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418907713/image_1418907713.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click to find out why PFE stock is a Hold.",
      "url": "https://finnhub.io/api/news?id=3bc12cc409f629dd3693f54ea9819d033d3bb70d51bf572bc2992b722db36ac2"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer signs global licensing deal with 3SBio for bispecific antibody",
    "summary": "Pfizer will pay $1.25 upfront, and 3SBio could earn up to $4.8bn in milestone payments.",
    "url": "https://finnhub.io/api/news?id=a57b2077052dfae1f62daedf5e8b6f7baa46ea59ad3aee875e6bbbed0b312e62",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747730252,
      "headline": "Pfizer signs global licensing deal with 3SBio for bispecific antibody",
      "id": 134609207,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer will pay $1.25 upfront, and 3SBio could earn up to $4.8bn in milestone payments.",
      "url": "https://finnhub.io/api/news?id=a57b2077052dfae1f62daedf5e8b6f7baa46ea59ad3aee875e6bbbed0b312e62"
    }
  },
  {
    "ts": null,
    "headline": "These 3 Dividend Stocks Yield More Than 6% and Their Payouts Look Safe",
    "summary": "If you see a stock that pays 6% in dividends, you might assume it's too risky -- but that's not always the case.  In some situations, a yield can grow to such heights because investors have been dumping the stock.  This can occur due to concerns around a company's business, including poor financial results.",
    "url": "https://finnhub.io/api/news?id=7d0f3bf043050c00bd29c32c2994e4018bae15086d7b20a5b8939360dd829be5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747727400,
      "headline": "These 3 Dividend Stocks Yield More Than 6% and Their Payouts Look Safe",
      "id": 134609149,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "If you see a stock that pays 6% in dividends, you might assume it's too risky -- but that's not always the case.  In some situations, a yield can grow to such heights because investors have been dumping the stock.  This can occur due to concerns around a company's business, including poor financial results.",
      "url": "https://finnhub.io/api/news?id=7d0f3bf043050c00bd29c32c2994e4018bae15086d7b20a5b8939360dd829be5"
    }
  },
  {
    "ts": null,
    "headline": "Chinese Biotech Stocks Surge After 3SBio's $6 Billion Licensing Deal With Pfizer -- Update",
    "summary": "Chinese Biotech Stocks Surge After 3SBio's $6 Billion Licensing Deal With Pfizer -- Update",
    "url": "https://finnhub.io/api/news?id=0c69c5f34397b4058675adfb82ee8c3ce63074a492fef8afa20d8b95f8e88e9e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747714740,
      "headline": "Chinese Biotech Stocks Surge After 3SBio's $6 Billion Licensing Deal With Pfizer -- Update",
      "id": 134615001,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Chinese Biotech Stocks Surge After 3SBio's $6 Billion Licensing Deal With Pfizer -- Update",
      "url": "https://finnhub.io/api/news?id=0c69c5f34397b4058675adfb82ee8c3ce63074a492fef8afa20d8b95f8e88e9e"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) Inks $6 Billion Cancer Drug Licensing Agreement with China’s 3SBio",
    "summary": "On May 19, Pfizer Inc. (NYSE:PFE) announced it had entered into a licensing agreement valued at approximately $6 billion with Chinese biopharmaceutical firm 3SBio Inc. for the development, production, and commercialization of a potential cancer treatment. According to Pfizer Inc. (NYSE:PFE), the drug candidate is being tested for use against non-small cell lung cancer, metastatic […]",
    "url": "https://finnhub.io/api/news?id=aea995ae97d096439e74da7a265d6a54adf61577e3c693dcccd7c34d398eb14b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747713485,
      "headline": "Pfizer Inc. (PFE) Inks $6 Billion Cancer Drug Licensing Agreement with China’s 3SBio",
      "id": 134609209,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "On May 19, Pfizer Inc. (NYSE:PFE) announced it had entered into a licensing agreement valued at approximately $6 billion with Chinese biopharmaceutical firm 3SBio Inc. for the development, production, and commercialization of a potential cancer treatment. According to Pfizer Inc. (NYSE:PFE), the drug candidate is being tested for use against non-small cell lung cancer, metastatic […]",
      "url": "https://finnhub.io/api/news?id=aea995ae97d096439e74da7a265d6a54adf61577e3c693dcccd7c34d398eb14b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: licensing agreement outside China with 3SBio",
    "summary": "Pfizer announced Monday evening an agreement with Chinese group 3SBio, granting the US company an exclusive license for the development, manufacture and commercialization, outside China, of SSGJ-707,...",
    "url": "https://finnhub.io/api/news?id=a139ceb04d3864987f7ab41055b28bd62c1631d717294f857593840ed0924dc5",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747713381,
      "headline": "Pfizer: licensing agreement outside China with 3SBio",
      "id": 134606200,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Pfizer announced Monday evening an agreement with Chinese group 3SBio, granting the US company an exclusive license for the development, manufacture and commercialization, outside China, of SSGJ-707,...",
      "url": "https://finnhub.io/api/news?id=a139ceb04d3864987f7ab41055b28bd62c1631d717294f857593840ed0924dc5"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake",
    "summary": "Pfizer also plans to make a $100 million equity investment in the Chinese biotechnolgoy company after the transaction closes, which is expected to happen in the third quarter.  Shares in 3SBio surged 35% in Hong Kong trade on Tuesday, valuing the Chinese biopharmaceutical company at nearly $6 billion.  The deal underscores solid demand for Chinese assets from global pharmaceutical firms looking to replenish their drug pipelines and boost their presence in the China market, even as the trade war between Beijing and Washington and potential U.S. tariffs on pharmaceuticals pose risks to the sector.",
    "url": "https://finnhub.io/api/news?id=520fce4517e4e93069599146c91d42f353f0ca9a53c86f3e72c86f64ff517353",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747701347,
      "headline": "Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake",
      "id": 134609210,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer also plans to make a $100 million equity investment in the Chinese biotechnolgoy company after the transaction closes, which is expected to happen in the third quarter.  Shares in 3SBio surged 35% in Hong Kong trade on Tuesday, valuing the Chinese biopharmaceutical company at nearly $6 billion.  The deal underscores solid demand for Chinese assets from global pharmaceutical firms looking to replenish their drug pipelines and boost their presence in the China market, even as the trade war between Beijing and Washington and potential U.S. tariffs on pharmaceuticals pose risks to the sector.",
      "url": "https://finnhub.io/api/news?id=520fce4517e4e93069599146c91d42f353f0ca9a53c86f3e72c86f64ff517353"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Enters into Exclusive Licensing Agreement with 3SBio",
    "summary": "NEW YORK, May 20, 2025--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. SSGJ-707 has shown initial effic",
    "url": "https://finnhub.io/api/news?id=106a4c378b2f85bb4dd8a9a30cd3c6dcea2ed12aea9a3c19675c8b6362e5c164",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747699200,
      "headline": "Pfizer Enters into Exclusive Licensing Agreement with 3SBio",
      "id": 134609211,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, May 20, 2025--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. SSGJ-707 has shown initial effic",
      "url": "https://finnhub.io/api/news?id=106a4c378b2f85bb4dd8a9a30cd3c6dcea2ed12aea9a3c19675c8b6362e5c164"
    }
  }
]